Nicolò Manaresi

Italian Angels for Growth (IAG) is the leading Network-Powered Venture Capital investor in Italy: more than 600 business angels from the entrepreneurial, financial, and industrial worlds have come through the IAG network, investing time, expertise, and capital for the growth of innovative startups. Among the first Italian investors in the early stage, IAG, in sixteen years of activity, has analyzed more than 7,000 investment opportunities and closed more than 125 deals, for a total of more than 550 million euros invested by IAG members and its co-investors, which have generated +1100 jobs and 310 million in generated revenues, creating an ecosystem involving more than 150 national and international partners. Four operating offices: Milan, Rome, Florence and Udine. info@italianangels.net

Menarini Silicon Biosystems offers unique rare cell technologies and solutions that provide clinical researchers with access to unparalleled resolution in the study of cells and their molecular characterization. The company’s CELLSEARCH® and DEPArray™ technologies together provide an end-to-end solution for enumeration and sorting of rare cells with single-cell precision. Menarini Silicon Biosystems, based in Bologna, Italy, and Huntingdon Valley, PA, US, is a wholly-owned subsidiary of the Menarini Group, a multinational pharmaceutical, biotechnology, and diagnostics company headquartered in Florence, Italy, with 17,640 employees in 136 countries. Read our Netiquette here: www.siliconbiosystems.com/netiquette

Italian Angels for Growth (IAG) is the leading Network-Powered Venture Capital investor in Italy: more than 600 business angels from the entrepreneurial, financial, and industrial worlds have come through the IAG network, investing time, expertise, and capital for the growth of innovative startups. Among the first Italian investors in the early stage, IAG, in sixteen years of activity, has analyzed more than 7,000 investment opportunities and closed more than 125 deals, for a total of more than 550 million euros invested by IAG members and its co-investors, which have generated +1100 jobs and 310 million in generated revenues, creating an ecosystem involving more than 150 national and international partners. Four operating offices: Milan, Rome, Florence and Udine. info@italianangels.net

Menarini Silicon Biosystems offers unique rare cell technologies and solutions that provide clinical researchers with access to unparalleled resolution in the study of cells and their molecular characterization. The company’s CELLSEARCH® and DEPArray™ technologies together provide an end-to-end solution for enumeration and sorting of rare cells with single-cell precision. Menarini Silicon Biosystems, based in Bologna, Italy, and Huntingdon Valley, PA, US, is a wholly-owned subsidiary of the Menarini Group, a multinational pharmaceutical, biotechnology, and diagnostics company headquartered in Florence, Italy, with 17,640 employees in 136 countries. Read our Netiquette here: www.siliconbiosystems.com/netiquette

ETH Zurich – Where the future begins Freedom and individual responsibility, entrepreneurial spirit and open-mindedness: ETH Zurich stands on a bedrock of true Swiss values. Our university for science and technology dates back to the year 1855, when the founders of modern-day Switzerland created it as a centre of innovation and knowledge. At ETH Zurich, students discover an ideal environment for independent thinking, researchers a climate which in-spires top performance. Situated in the heart of Europe, yet forging connections all over the world, ETH Zurich is pioneering effective solutions to the global challenges of today and tomorrow. Some 530 professors teach around 20,500 students – including 4,100 doctoral students – from over 120 countries. Their collective research embraces many disciplines: natural sciences and engineering scienc-es, architecture, mathematics, system-oriented natural sciences, as well as management and social sci-ences. The results and innovations produced by ETH researchers are channelled into some of Switzer-land’s most high-tech sectors: from computer science through to micro- and nanotechnology and cutting-edge medicine. Every year ETH registers around 90 patents and 200 inventions on average. Since 1996, the university has produced a total of 380 commercial spin-offs. ETH also has an excellent reputation in scientific circles: 21 Nobel laureates have studied, taught or researched here, and in international league tables ETH Zurich regularly ranks as one of the world’s top universities.